PatientsVille.com Logo


Lovenox Medical Research Studies

Up-to-date List of Lovenox Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Lovenox Medical Research Studies

Rank Status Study
1 Recruiting Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients
Condition: Malignant Female Reproductive System Neoplasm
Intervention: Drug: Enoxaparin, Heparin
Outcome Measure: Safety
2 Not yet recruiting Prophylactic Use of Sodium Enoxaparin for Venous Thromboembolism in High-Risk Abdominal Surgery
Condition: Venous Thromboembolism
Interventions: Drug: Sodium enoxaparin;   Drug: Sodium Enoxaparin clexane
Outcome Measures: Evaluation of Sodium enoxaparin to demonstrate non-inferiority;   Safety of sodium enoxaparine;   Compare the incidence of venous thromboembolism and pulmonar embolism
3 Recruiting Comparison of Anti-Xa Activity of ENOXA ® Versus Lovenox ® in Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Factor X
Interventions: Drug: ENOXA®;   Drug: Lovenox®
Outcome Measures: anti-Xa activity;   adverse events
4 Recruiting Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia
Condition: Preeclampsia
Interventions: Drug: Lovenox® (enoxaparin);   Drug: Aspegic ® (Aspirin)
Outcome Measures: The primary outcome is a composite morbidity that may occur : maternal death, or perinatal death, or preeclampsia, or abruptio placenta, or fetal growth restriction.;   Recurrence of preeclampsia alone;   Recurrence of severe preeclampsia;   Fetal growth restriction alone;   Severe fetal growth restriction (< 5th percentile);   Perinatal death alone;   Neonatal death;   Abruption alone;   Maternal death;   Fetal loss (10-21 weeks);   Fetal death;   Recurrence of preeclampsia controlled for thrombophilia analysis (polymorphism of factor V Leiden, prothrombin G20210A gene polymorphism);   Recurrence of preeclampsia controlled for angiogenic factors (free VEGF and PlGF, sFlt1, sEng);   Neonatal morbidity (NICU transfer, length of hospitalization, mechanical ventilation > 24 hours, respiratory distress syndrome, necrotizing enterocolitis, periventricular leucomalacia, bronchopulmonary dysplasia, intraventricular hemorrhage grade III-IV);   Enoxaparin toxicity: hemorrhage, skin reaction, thrombocytopenia (<100000/µL) related to heparin;   Bone fracture
5 Not yet recruiting Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity
Condition: Obesity
Interventions: Drug: 40mg Enoxaparin;   Drug: 60mg Enoxaparin;   Other: Control
Outcome Measure: Anti-factor Xa plasma levels
6 Recruiting A Pilot Study Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients
Conditions: Deep Venous Thrombosis;   Pulmonary Embolism
Interventions: Drug: Enoxaparin;   Drug: Fondaparinux
Outcome Measures: To estimate the prevalence of asymptomatic deep venous thrombosis and pulmonary emboli in obese patients undergoing bariatric surgery.;   To assess the relationship of Anti-factor Xa levels and the occurrence of deep venous thrombosis and pulmonary emboli in bariatric patients receiving standard dose of anticoagulation (enoxaparin/Lovenox or fondaparinux/Arixtra).
7 Recruiting Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome
Conditions: Fetal Demise;   Fetal Growth Restriction;   Preeclampsia;   Abruptio Placentae;   Thromboembolism
Intervention: Drug: enoxaparin
Outcome Measures: placental syndrome or thromboembolic event;   enoxaparin side effects
8 Unknown  Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin
Conditions: Deep Vein Thrombosis;   Enoxaparin;   Anticoagulants
Intervention: Drug: Enoxaparin
Outcome Measures: Presence or absence of ultrasound findings in favor of asymptomatic DVT;   To evaluate the efficacy and tolerability clinical Enox ® in these patients.
9 Unknown  Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
Conditions: Non ST Segment Elevation Myocardial Infarction;   Unstable Angina
Intervention: Drug: Enoxaparin
Outcome Measures: Frequency of death and infarction within 30 days after the admission in emergency;   Comparing the effectiveness and safety of the two formulations in patients with NSTE-ACS and high-risk ones
10 Not yet recruiting Adjusted Value of Thromboprophylaxis in Hospitalized Obese Patients: A Comparative Study of Two Regimens of Enoxaparin
Condition: Thromboprophylaxis in Hospitalized Obese Patients
Intervention: Drug: Enoxaparin
Outcome Measures: Evaluate the anti- Xa activity between a standard treatment by Enoxaparin (40mg/ day) and an adapted dose of enoxaparin (60 mg/day) for thromboprophylaxis in obese patients hospitalized;   Compare the occurrence of symptomatic venous thrombosis (deep venous thrombosis or pulmonary embolism) and the relevant bleeding events according to the enoxparin treatments
11 Recruiting Enoxaparin Dosing in Obesity
Condition: Obesity
Intervention: Drug: Enoxaparin
Outcome Measures: Proportion of patients with an initial therapeutic anti-Xa level at steady state in each group;   Time to therapeutic anti-Xa level for both groups
12 Recruiting Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis
Conditions: Obesity;   Obesity, Morbid;   Pregnancy;   Complications; Cesarean Section;   Venous Thromboembolism;   Postpartum Deep Phlebothrombosis;   Pulmonary Embolism
Intervention: Drug: Enoxaparin
Outcome Measures: Anti Xa level;   Anti Xa
13 Recruiting Enoxaparin Versus Aspirin in Patients With Cancer and Stroke
Condition: Cancer Patients First-ever Acute Ischemic Stroke
Interventions: Drug: Enoxaparin;   Drug: Aspirin
Outcome Measures: Safety Outcomes;   Feasibility Outcomes;   Efficacy Outcomes
14 Unknown  Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)
Conditions: Venous Thromboembolism;   Traumatic Brain Injury
Interventions: Drug: enoxaparin;   Drug: placebo
Outcome Measures: Worsening of TBI hemorrhage pattern on any scheduled or PRN CT scans after the initiation of treatment;   extracranial hemorrhagic complications;   Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
15 Recruiting Weight Based Enoxaparin in Trauma Patients
Condition: Venous Thromboembolism
Intervention: Drug: Dosing of enoxaparin for VTE prophylaxis
Outcome Measures: Asymptomatic lower-extremity DVT identified during hospitalization;   Symptomatic lower extremity DVT during hospitalization and at 90 days;   Asymptomatic proximal DVT during hospitalization;   Symptomatic proximal DVT during hospitalization and at 90 days;   Symptomatic upper-extremity DVT during hospitalization and at 90 days;   Symptomatic PE during hospitalization and at 90 Days;   Major Bleeding
16 Recruiting Venous Thromboembolic Prophylaxis After Major Trauma: A Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
Conditions: Venous Thromboembolic Disease;   Deep Vein Thrombosis;   Pulmonary Embolism
Interventions: Drug: 5000 Units unfractionated Heparin Q 8 hours;   Drug: 30mg enoxaparin Q12 hours
Outcome Measures: Lower extremity deep vein thrombosis;   Pulmonary Embolus;   Bleeding event;   Heparin induced thrombocytopenia
17 Recruiting A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Interventions: Drug: cisplatinum or carboplatin and e.g.etoposide.;   Drug: cisplatinum or carboplatin and e.g.etoposide+enoxaparin
Outcome Measures: Significant increase of overall survival;   Toxicity
18 Unknown  The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients
Conditions: Venous Thrombosis;   Critical Illness
Intervention: Drug: Enoxaparine
Outcome Measures: To determine the effect of the dosing protocols of enoxaparin for critically ill patients on aFXa activity;   bleeding/thrombotic complications
19 Recruiting The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin
Conditions: Acute Coronary Syndrome;   Venous Thromboembolism;   Atrial Fibrillation;   Hypercoagulability
Outcome Measure:
20 Unknown  Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity
Conditions: Colorectal Cancer;   Liver Metastases;   Irradiation Damage;   Radiation Induced Liver Disease
Interventions: Drug: Pentoxifylline;   Drug: Ursodeoxycholic Acid;   Drug: Enoxaparin
Outcome Measures: HDR-brachytherapy isodose (measured in Gy) that corresponds to the metastases without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.;   HDR-brachytherapy isodose (measured in Gy) that corresponds to the irradiated liver tissue without enhancement of Gd-EOB-DTPA in MR imaging using an axial T1 THRIVE sequence.;   Correlation between the HDR brachytherapy isodose that corresponds to damaged live tissue as defined by missing Gd-EOB-DTPA enhancement in MR imaging and liver-specific laboratory values.;   Quality of live.;   Safety of the study drugs.

These studies may lead to new treatments and are adding insight into Lovenox etiology and treatment.

A major focus of Lovenox research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Lovenox